The most important implication is that most cases of childhood leukemia are likely to be preventable.
It might be done in the same way that is currently under consideration for autoimmune disease or allergies -- perhaps with simple and safe interventions to expose infants to a variety of common and harmless 'bugs'." Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said: "This research has been something of a personal, 30-year quest for Professor Mel Greaves -- who is one of the UK's most influential and iconic cancer researchers.
"This body of research is a culmination of decades of work, and at last provides a credible explanation for how the major type of childhood leukemia develops.
The research strongly suggests that ALL has a clear biological cause, and is triggered by a variety of infections in predisposed children whose immune systems have not been properly primed.
Patients received cyclophosphamide 1 g/m2/d on days -6, -5, -4; melphalan 70 mg/m2 on days -3, -2 and topotecan 3.0 to 3.5 mg/m2/d on days -6 to -2. Toxicity (Bearman Toxicity Criteria) was mostly limited to grade 1 - 2 mucositis and grade 1 diarrhea. The overall response rate at 3 months post transplantation was 89% with 17% CR, 2 of those in refractory patients.
The overall response rate in refractory patients was 67%.
His work has cut through the myths about childhood leukemia and for the first time set out a single unified theory for how most cases are caused.
"It's exciting to think that, in future, childhood leukemia could become a preventable disease as a result of this work.
It happens when these cells don't mature properly, and grow too fast. "Scientist reveals likely cause of childhood leukemia: Landmark paper sets out 'unified theory' for cause of childhood leukemia -- and finds it is likely to be preventable." Science Daily. The results of the study show that the incidence of new cases of myeloblastic leukemia ...
The efficacy and safety of the new fusion protein has been demonstrated in mouse models of aggressive human leukemia using leukemia cells taken directly from patients with ALL.